EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023
18 avr. 2023 09h00 HE
|
EvolveImmune
Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1 Checkpoint Pathway Engineered CAR-T Cells Lacking Exhaustion-Associated Genes Mediate Improved...
Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR
29 janv. 2020 16h07 HE
|
Equillium
LA JOLLA, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Reports Second Quarter 2019 Financial Results and Recent Highlights
12 août 2019 16h07 HE
|
Equillium
Initiated Phase 1b EQUIP proof-of-concept trial evaluating itolizumab (EQ001) for the treatment of uncontrolled asthma Investigational New Drug (IND) application accepted by FDA for itolizumab for...
Equillium Granted U.S. FDA Fast Track Designation for EQ001 for the Treatment of Acute Graft-Versus-Host Disease
19 déc. 2018 08h06 HE
|
Small Logo
LA JOLLA, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the...
Equillium Reports Third Quarter 2018 Financial Results and Recent Highlights
15 nov. 2018 16h07 HE
|
Equillium, Inc.
Completes Successful Initial Public Offering Raising Gross Proceeds of Approximately $71.6 Million On-Track for Early 2019 Initiation of Phase 1b/2 Trial of EQ001 in Acute Graft-Versus-Host Disease ...
eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 Add-on (CPI-A) Trial in Combination with Checkpoint Inhibitors to Treat Patients with Insufficient Response to Checkpoint Inhibitors Alone
27 juil. 2018 07h30 HE
|
eFFECTOR Therapeutics
SAN DIEGO, July 27, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin’s Lymphoma
06 juin 2018 07h30 HE
|
eFFECTOR Therapeutics
SAN DIEGO, June 06, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
eFFECTOR Initiates Randomized Dosing in Phase 2 Checkpoint Combination Trial of eFT508 and Avelumab in Colorectal Cancer
11 mai 2018 07h30 HE
|
eFFECTOR Therapeutics
SAN DIEGO, May 11, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
eFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal Chemistry
26 avr. 2018 07h30 HE
|
eFFECTOR Therapeutics
SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that...
eFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual Meeting
16 avr. 2018 08h00 HE
|
eFFECTOR Therapeutics
SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced a...